Endocrine Abstracts

Regulators are concerned about the potential for environmental chemicals such as agrochemicals and their metabolites to perturb hormone systems. This has led to recommendations for the testing of potential endocrine disrupting chemicals1. The Steroidogenesis H295R assay is an in vitro cell model used to investigate compound effects on steroid hormone biosynthesis, specifically 17β-estradiol (E2) and testosterone (T). The human H295R adreno-carcinoma ce...

Background: Obesity is a common risk factor for obstructive sleep apnoea (OSA) and polycystic ovary syndrome (PCOS).Objective: To examine the prevalence of OSA in women with PCOS.Search sources: Electronic databases [Medline, Embase, Cinahl, PsycInfo, Scopus, Web of Science, Opengrey, and Cochrane Central Register of Controlled Trials], conference abstracts, and reference lists of relevant articles. The...

Background: Obesity is a common risk factor for obstructive sleep apnoea (OSA) and polycystic ovary syndrome (PCOS).Objective: To examine the prevalence of OSA in women with PCOS.Search sources: Electronic databases [Medline, Embase, Cinahl, PsycInfo, Scopus, Web of Science, Opengrey, and Cochrane Central Register of Controlled Trials], conference abstracts, and reference lists of relevant articles. The...

Introduction: Lutetium-177 Oxodotreotide (Lutathera) is a targeted molecular radiotherapy treatment for advanced, inoperable, progressive neuro-endocrine tumours. We present our experience of Lutathera therapy with particular focus on our experience implementing treatment as a day-case procedure, and assessment of adherence to treatment quality standards surrounding the administration.Aims: To assess safety of Lutathera as a day-case treatment.<p cla...

Objective: We reported 3 patients with primary aldosteronism who presented at times of high plasma LH, and had somatic CTNNB1 mutations causing ˜100-fold elevation of LHCGR in their APAs (Teo et al. NEJM 2015). Subsequently we identified 4 further patients, but the association with pregnancy was not found by others. Whole exome sequencing (WES) of an APA diagnosed at onset of puberty suggests an explanation.Method: WES of tumour and blood w...

Primary aldosteronism (PA) is the cause of 5–10% of hypertension, surgically curable in patients with unilateral aldosterone-producing adenomas (APAs). However <1% of patients are currently diagnosed and cured. Newer and simpler modalities of diagnosis and treatment are required. The aim of FABULAS (a feasibility study of endoscopic ultrasound-guided ablation as a non-surgical, adrenal sparing treatment for aldosterone-producing adenomas) is to determine in 30 patient...

Background: Primary aldosteronism (PA) is responsible for 5-10% of all cases of HTN. The current gold standard test for determining the side of aldosterone hypersecretion is adrenal vein sampling (AVS). 11C-Metomidate PET/CT (METO-PET) has recently emerged as a potential non-invasive alternative to AVS. As 11C-Metomidate is concentrated within ‘hyperfunctioning’ nodules, METO-PET potentially not only identifies the side, but the exact site of al...

Introduction: Tumours with aryl hydrocarbon receptor interacting (AIP) mutations often show an unusually aggressive and invasive clinical course as up to 80% of AIP positive pituitary adenomas have a certain degree of extrasellar extension. The exact mechanisms by which AIP inactivation promotes an aggressive behaviour remain unknown. The majority of adenohypophysis is composed of sinuous cords of epithelial cells and consequently, molecules that can induce remodellin...

Background: Primary aldosteronism (PA) is now recognised to account for 5–10% of all cases of hypertension (and 20–25% of refractory hypertension). For patients with a demonstrable unilateral cause, adrenalectomy offers the potential for cure of PA, although resolution of hypertension occurs in only ~50% of patients. We have examined histological appearances and radiological features in patients with APAs undergoing adrenalectomy in an attempt to further our understa...

The pattern of food consumption has a profound influence on metabolic hormone secretion, but until recently only crude manipulations of feeding events have been possible in rodents. Using a CLAMS-based system to overcome this problem, we have investigated the effect of 3 weeks of grazing (consumption of 1/24th of the total daily food intake of ad libitum-fed controls every 30 min during the dark phase (18.00–06.00 h)) and meal feeding (three 1-h periods of ad...